Last --
Change Today 0.00 / 0.00%
Volume 0.0
MSC On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

meridex software corp (MSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERIDEX SOFTWARE CORP (MSC)

Related News

No related news articles were found.

meridex software corp (MSC) Related Businessweek News

No Related Businessweek News Found

meridex software corp (MSC) Details

InMed Pharmaceuticals Inc., a biopharmaceutical company, engages in the development of cannabis-based botanical and non-botanical therapies. Its Drug Discovery and Development division utilizes its proprietary Cannabinoid Drug Design Platform to identify new bioactive compounds within the marijuana plant that interact with various gene responsible for specific diseases. The company’s Cultivation and Breeding division researches and develops individual strains and clones for producing the raw material bases for future pharmaceutical research. It focuses on various therapeutic areas, including glaucoma, inflammation/pain/arthritis, Huntington's and Epilepsy diseases, diabetes, obesity, cancer, and angiogenesis. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. is based in Vancouver, Canada.

meridex software corp (MSC) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: --
Chief Financial officer
Total Annual Compensation: C$12.9K
Compensation as of Fiscal Year 2013.

meridex software corp (MSC) Key Developments

InMed Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

InMed Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Cannabis Technologies Inc. will Change its Name to InMed Pharmaceuticals Inc

Effective October 21, 2014, Cannabis Technologies Inc. will change its name to InMed Pharmaceuticals Inc.

Cannabis Technologies Inc. Announces Second Therapy-CTI 091

Cannabis Technologies Inc. announced the development of a therapy containing a proprietary mixture of cannabinoids and non-cannabis based active ingredients CTI-091 for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression. CTI-091 is designed to enhance retention and absorption of the key ingredients around the target site and designed for the relief of joint pain and swelling. Currently the formulation is in preclinical stage of development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSC:CN C$0.00 CAD 0.00

MSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation MSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDEX SOFTWARE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at